EWTX
NASDAQ · Pharmaceuticals
Edgewise Therapeutics Inc
$29.06
-0.99 (-3.29%)
Financial Highlights (FY 2025)
Revenue
407.17M
Net Income
72.15M
Gross Margin
40.0%
Profit Margin
17.7%
Rev Growth
+16.1%
D/E Ratio
0.29
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 40.0% | 40.0% | 40.0% |
| Operating Margin | 25.4% | 24.9% | 27.8% |
| Profit Margin | 17.7% | 21.2% | 16.8% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 407.17M | 429.50M | 324.39M |
| Gross Profit | 162.94M | 171.88M | 129.82M |
| Operating Income | 103.52M | 106.91M | 90.28M |
| Net Income | 72.15M | 91.13M | 54.38M |
| Gross Margin | 40.0% | 40.0% | 40.0% |
| Operating Margin | 25.4% | 24.9% | 27.8% |
| Profit Margin | 17.7% | 21.2% | 16.8% |
| Rev Growth | +16.1% | +0.2% | +22.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 612.30M | 535.89M | 602.65M |
| Total Equity | 2.10B | 2.18B | 2.21B |
| D/E Ratio | 0.29 | 0.25 | 0.27 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 147.48M | 172.82M | 113.17M |
| Free Cash Flow | 69.60M | 65.40M | 42.96M |